Rua Bioscience Results of 2021 Annual Shareholders’ Meeting

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com



FOR PUBLIC RELEASE
NZX Limited
Wellington

Wednesday, 20 October 2021


Results of Rua Bioscience Limited’s 2021 Annual Shareholders’ Meeting

At Rua Bioscience Limited’s hybrid Rua Bioscience Annual Shareholders’ Meeting (held online and in
Gisborne yesterday) shareholders were asked to vote on two ordinary resolutions, which were
supported by the Board.

As required by NZX Listing Rule 6.1, all voting was conducted by a poll.

The resolutions passed by the shareholders were:
× Resolution One: That the Board be authorised to fix the auditor’s remuneration.
× Resolution Two: That Martin Smith be re-elected as a director of Rua.

Detail of the total number of votes cast in person or by a proxy are as follows:

Resolution For Against Abstain
That the Board be authorised to fix the auditor’s
remuneration.
34,632,917
100.00%
1,000
0.00%
0
That Martin Smith be re-elected as a director of
Rua.
33,963,808
99.47%
181,611
0.53%
473,498


Authority for this Announcement
Name of the person authorised to make this
announcement
Hamish White
Contact person for this announcement Chief Financial Officer & Company Secretary
Contact phone number +64 (21) 050 5795
Contact email address Hamish.white@ruabio.com
Date of release through MAP 20/9/2021


Director Independence
As required by the NZX Listing Rules, the Board of Rua Bioscience has determined that the following
Directors are Independent Directors:
× Trevor Burt
× Anna Stove
× Martin Smith

Ends

MEETING RESULTS ANNOUNCEMENT

PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com


For more information, please visit
www.ruabio.com
or contact:
Media
Kerry Donovan
Communications Manager
+64 (21) 128 7689
kerry.donovan@ruabio.com


Investors
Hamish White

Chief Financial Officer

+64 (21) 050 5795
Hamish.white@ruabio.com

About Rua Bioscience
Rua Bioscience is a New Zealand pharmaceutical company aiming to produce cannabinoid derived
medicines for both export and local markets. Rua has been an early mover in the sector and was the
first private company in New Zealand to receive a licence to cultivate Cannabis for research
purposes. Founded in 2017 in Ruatorea as a subsidiary of charitable company Hikurangi Enterprises
Limited, Rua is underpinned by its mission to heal the people and heal the land. It is committed to
New Zealand's Te Tairāwhiti (East Coast) region and its local community. The Company has
completed facilities for cultivation and manufacturing and is currently going through the GMP
certification process. www.ruabio.com